Avoro Capital Advisors
Crossover fundNew York · Seed–Series A · 22 people tracked
Investment thesis
Avoro Capital Advisors seeks scientific breakthroughs with the potential to address unmet medical needs, driven by intellectual curiosity. The firm aims to identify unique or mispriced investment opportunities, analyzing complex situations and supporting companies with both financial and intellectual resources across the lifecycle of an investment. It emphasizes disciplined risk management, evaluating macro and company-specific risks, and may employ tactical and fundamental hedges within its portfolio construction while carefully weighing position sizing and liquidity considerations.
Source: firm website, verified Aug 11, 2026.
Team · 22 people
from the firm's website & public directories
What they invest in
from 42 of 69 portfolio companiesBiotech ×39Healthtech ×27Medical Devices ×12Deep Tech ×5Digital Health ×3AI & Machine Learning ×2Cloud Computing ×1Fintech ×1
HQs:United States×24Denmark×1Netherlands×1
Investments · 69 tracked
founders shown can be your intro pathBy year:2021 · 22018 · 12015 · 25 dated
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
ROBERT ABRAHAM(Director)DAVID BONDERMAN(Director)TODD SISITSKY(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)
Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options.
BiotechHealthtech
BiotechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jose Rivera(Executive Officer)Carl Gordon(Director)Jean-Francois Formela(Director)John Leonard(Executive Officer, Director)Rachel Haurwitz(Director)
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
HEIDI HENSON(Executive Officer)TROY WILSON(Executive Officer, Director)ANNETTE NORTH(Executive Officer)PINGDA REN(Executive Officer)YI LIU(Executive Officer)ANTONIO GUALBERTO(Executive Officer)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Monte Rosa Therapeutics is a biopharmaceutical company developing molecular glue degrader (MGD) therapeutics using its QuEEN discovery engine, targeting oncology, neuroscience, and immune-mediated diseases.
AI & Machine LearningBiotechHealthtechBoston, US
Alexander Mayweg(Director)Bradley Bolzon(Director)Markus Warmuth(M.D., Chief Executive Officer)Kim Blackwell(Director)Sharon Townson(Ph.D., Chief Scientific Officer)John Castle(Ph.D., Chief Data and Information Officer)
BiotechIselin, US
Lawrence A. Kenyon(Executive Officer, Director)Jeff Evanson(Executive Officer)Pankaj Mohan(Executive Officer, Director)Donald Griffith(Director)Scott Canute(Director)Todd Brady(Director)
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and liver diseases, with a lead candidate VK2735, a dual GLP-1/GIP receptor agonist in Phase 3 obesity trials in both oral and injectable formulations.
BiotechHealthtech
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical Devices
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical Devices
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a global rare disease biotechnology company that develops medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)Craig A. Wheeler(Director)Ted W. Love(Director)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)Margaret G. McGlynn(Director)
argenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies.
BiotechHealthtech
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)
Assembly Bio is a biotechnology company developing antiviral therapies for serious viral and liver diseases, including treatments for recurrent genital herpes and chronic hepatitis.
Biotech
BiotechBuffalo, US
Flint Besecker(Executive Officer, Director)Li Shen(Executive Officer)Simon Pedder(Executive Officer)Johnson Lau(Executive Officer, Director)William Zuo(Executive Officer)Kim Campbell(Director)
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Novartis is a pharmaceutical company that develops medicines and reports financial and nonfinancial results to investors.
BiotechHealthtechCambridge, US
Tom Maniatis(Director)Michael R. Cooper(Executive Officer)Anthony Evnin(Director)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)
Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.
BiotechHealthtechNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Carl Goldfischer, M.D.(Director)Pol Boudes(Executive Officer)Kurt von Emster(Director)Hari Kumar, Ph.D.(Director)Charles A. McWherter, Ph. D.(Executive Officer)
Fennec Pharmaceuticals is a biotechnology company focused on treatments for cancer patients who experience hearing loss caused by chemotherapy.
BiotechHealthtechResearch Triangle Park, US
Adrian Haigh(Director)Steven Skolsky(Director)Chris Rallis(Director)Krysia Lynes(Executive Officer)Rostislav Raykov(Executive Officer, Director)Khalid Islam(Director)
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that discovers and develops oral cancer therapies for disease areas with high unmet need.
BiotechHealthtechNewton, US
Peter Honig(Director)Barry E. Greene(Director)Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)
Krystal Biotech develops and commercializes redosable gene therapies to treat severe, rare, and life-threatening diseases with limited or no approved treatments.
BiotechMedical DevicesPittsburgh, US
Doug Norby(Director)Dino Rossi(Director)Suma M. Krishnan(Director)Krish S. Krishnan(Executive Officer, Director)
BoardDan Janney(Director)
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)Seth H.Z. Fischer(Director)Tim M. Mayleben(Director)Nicole Vitullo(Director)
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Mark Throsby(Executive Officer)Gregory D. Perry(Director)Mark T. Iwicki(Director)Lionel M.S. Carnot(Director)Hui Liu(Executive Officer)Wolfgang Berthold(Director)
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)
BoardRoderick Wong(Director)Naveen Yalamanchi(Director)
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)HANS WIGZELL(Director)CLAUDE NICAISE(Director)DOUGLAS S. INGRAM(Executive Officer, Director)DAVID TYRONNE HOWTON(Executive Officer)MARY ANN GRAY(Director)
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer.
BiotechHealthtech
BiotechSouth San Francisco, US
Sandra Coufal(Director)Melissa Miksch(Executive Officer)Robert Alpern(Director)Gerrit Klaerner(Executive Officer, Director)
BoardDavid Bonita(Director)Klaus Veitinger(Director)
Exits · 10
IPOs and acquisitions across the tracked portfolioAllogeneNASDAQ: ALLOHemab TherapeuticsNASDAQ: COAGIntellia TherapeuticsNASDAQ: NTLAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRMonte Rosa TherapeuticsNASDAQ: GLUEOutlook TherapeuticsNASDAQ: OTLKScribe TherapeuticsNASDAQ: SCTXVikingtherapeuticsNASDAQ: VKTXVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companiesOutlook Therapeutics · finance.yahoo.com · Aug 3, 2026
Ascendis Pharma · dailypolitical.com · Jul 18, 2026
Allogene · investing.com · Jul 15, 2026
Kura Oncology · manilatimes.net · Jul 14, 2026
Scribe Therapeutics · allsci.com · Jul 6, 2026
Merus · finimize.com · Jun 24, 2026
Rocket Pharma · reuters.com · Mar 27, 2026
Adaptimmune · trial.medpath.com · Oct 27, 2025
Frequently asked questions
- What stage does Avoro Capital Advisors invest at?
- Avoro Capital Advisors invests at the Seed, Series A stages.
- What sectors does Avoro Capital Advisors focus on?
- Avoro Capital Advisors focuses on Biotech, Healthtech.
- Where is Avoro Capital Advisors located?
- Avoro Capital Advisors is headquartered in New York, US.
Co-investors · 10
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Pfizer Ventures is the corporate venture arm of Pfizer that invests in life science innovation across oncology, inflammation & immunology, cardiovascular, metabolic/obesity, and vaccines, as well as platform technology companies aligned with Pfizer's strategic focus areas.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Innovation Works is a Pittsburgh-based economic development organization and startup investor serving Southwestern Pennsylvania, running accelerator and hardware programs and supporting founders across robotics, life sciences, software and manufacturing.
Riverfront Ventures is an early-stage venture capital fund based in Pittsburgh that invests in early-growth stage technology companies, serving as the venture capital arm of Innovation Works.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Firms observed investing alongside Avoro Capital Advisors, from public investor directories. Shared companies are the overlap with Avoro Capital Advisors's recorded portfolio.
Similar investors
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.